- Complexity, cost, and content - three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing, Clin Chem Lab Med. 2019 Dec 13, pii: /j/cclm.ahead-of-print/cclm-2019-0977/cclm-2019-0977.xml.
- ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors, ATVB. 2019 Aug 8:ATVBAHA119312723. doi: 10.1161/ATVBAHA.119.312723
- Top-down mass spectrometric immunoassay for human insulin and its therapeutic analogs, J Proteomics. 2018 Mar 20;175:27-33
- Mass spectrometric studies of apolipoprotein proteoforms and their role in lipid metabolism and type 2 diabetes, Proteomes. 2017 Oct 15;5(4). pii: E27. doi: 10.3390/proteomes5040027
- Human proteoforms as new targets for clinical mass spectrometry protein tests, Expert Rev Proteomics. 2017 Aug;14(8):691-699.
- Mass spectrometry protein tests: Ready for primetime (or not), Expert Rev Proteomics. 2017 Jan;14(1):1-7.
Recent and Upcoming Conference Presentations
- Next Generation Clinical Diagnostics Assays. CPSA Shanghai, April 10-12, 2019, Shanghai, China.
- MS Protein Tests for the Clinical Laboratory. MSACL 2019, USA, March 31-April 4, Palm Springs, CA.
- Translating Mass Spectrometry-Based Protein Assays And The Challenging Road Ahead: Post-Translationally Modified Proteins As Biomarker Targets For Clinical MS Protein Tests. 5th EFLM-UEMS European Joint Congress on Laboratory Medicine, October 10-13, 2018, Antalya, Turkey.
- Post-Translationally Modified Proteins as Biomarker Targets for Clinical MS Tests. CPSA Analytics, May 7-8, 2018, Boston, MA.
- Mass Spectrometric Studies of Apolipoprotein Proteoforms and their Role in Lipid Metabolism and Type 2 Diabetes. MSACL 2018, USA, January 21-25, Palm Springs, CA.
- Translating MS protein assays into the clinic: The challenging road ahead, and the potential of posttranslationally modified proteins as new biomarker targets for clinical MS protein tests. HUPO 2017, September 17-21, Dublin, Ireland.